Medindia

X

Robust Annual Growth in the Renal Cell Carcinoma Drug Market Will be Driven by the Uptake of GlaxoSmithKline's Votrient/Patorma and the Launches of Premium-Priced Emerging Therapies

Tuesday, June 29, 2010 General News J E 4
Advertisement
In 2009, Angiogenesis Inhibitors Captured More Than Three-Quarters of the Renal Cell Carcinoma Drug Market, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Da...
S
Olivia Newton-John 'Gets Physical' as the Newest S...